Comment on

• Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

  Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. Rustin GJ, et al. J Clin Oncol. 2003 Aug 1;21(15):2815-22. doi: 10.1200/JCO.2003.05.185. Epub 2003 Jun 13. J Clin Oncol. 2003. PMID: 12807934 Clinical Trial.
• Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.

  Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Anderson HL, et al. J Clin Oncol. 2003 Aug 1;21(15):2823-30. doi: 10.1200/JCO.2003.05.186. Epub 2003 Jun 13. J Clin Oncol. 2003. PMID: 12807935 Clinical Trial.
• Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.

  Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ. Galbraith SM, et al. J Clin Oncol. 2003 Aug 1;21(15):2831-42. doi: 10.1200/JCO.2003.05.187. Epub 2003 Jun 13. J Clin Oncol. 2003. PMID: 12807936